QURE (uniQure NV) Short Interest


QURE uniQure NV QURE
50 GF Score
Price $41.79
GF Value $5.99
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

QURE vs ALMS, ARQT, DYN: Short Interest Comparison

For the Biotechnology subindustry, uniQure NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Short Interest distribution charts can be found below:

* The bar in red indicates where uniQure NV's Short Interest falls into.


QURE
50GF Score
uniQure NV QURE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is uniQure NV (QURE) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of $41.79 is trading 597.7% above its estimated GF Value™ of $5.99. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for QURE:

  • Short Interest:
  • GF Value™: $5.99 vs. price of $41.79 (597.7% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the QURE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
50GF Score

Get the complete analysis for QURE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price
$5.99
GF Value